share_log

PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement

PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement

PharmaDrug Inc. 宣佈成功完成非經紀私募配售
newsfile ·  02/09 05:30

Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce the closing of its previously announced non-brokered private placement raising total gross proceeds of $326,000 (the "Offering").

安大略省多倫多--(Newsfile Corp.,2024年2月8日)——PharmaDrug Inc.(CSE:PHRX)(場外交易鏈接:LMLF)(”PharmaDr“或者”公司“),很高興地宣佈其先前宣佈的非經紀私募募已結束,總收益爲32.6萬美元(”提供“)。

Pursuant to the Offering the Company issued 6,520,000 units ("Units") at a purchase price of $0.05 per Unit for aggregate gross proceeds of up to $326,000. Each Unit is comprised of one common share in the capital of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant being referred to herein as a "Warrant"). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.10 at any time up to February 8, 2026.

根據本次發行,公司發行了652萬個單位(”單位“)的收購價格爲每單位0.05美元,總收益高達326,000美元。每個單位由公司資本中的一股普通股組成(a”普通股“)以及一份普通股購買權證的一半(本文將每份完整認股權證稱爲”搜查令“)。每份認股權證使持有人有權在2026年2月8日之前的任何時候以0.10美元的行使價額外購買一股普通股。

Proceeds will be used for general corporate purposes.

所得款項將用於一般公司用途。

The securities issued pursuant to the Offering are subject to a hold period of four months and one day that expires on June 9, 2024.

根據本次發行發行的證券的持有期爲四個月零一天,將於2024年6月9日到期。

About PharmaDrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics ("Sairiyo"), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. PharmaDrug also owns 100% of SecureDose Synthetics Inc., a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.

關於 PharmaDrug Inc.
PharmaDrug是一家專業製藥公司,專注於受管制物質和天然藥物(例如迷幻藥和先前批准的藥物)的研究、開發和商業化。PharmaDrug擁有Sairiyo Therapeutics(“Sairiyo”)51%的股份。Sairiyo Therapeutics(“Sairiyo”)是一家生物技術公司,專門研究和重新配製成熟的天然藥物,目標是使其在美國和歐洲通過臨床試驗和相關的監管批准程序。Sairiyo目前正在開發頭孢他汀的專利配方,該藥物已顯示出經過第三方驗證的治療傳染病和罕見癌症的巨大潛力。PharmaDrug還擁有SecureDose Synthetics Inc. 的100%股份。SecureDose Synthetics Inc. 是一家藥物研發公司,專注於開發現有藥物的合成配方,以實現潛在的商業化和分銷。

For further information, please contact:

欲了解更多信息,請聯繫:

Robert J. Steen, Chairman and CEO
rob@pharmadrug.ca

羅伯特·斯蒂恩,董事長兼首席執行官
rob@pharmadrug.ca

(416) 400-7086

(416) 400-7086

Caution Regarding Forward-Looking Information:

關於前瞻性信息的注意事項:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大證券交易所尚未審查本新聞稿的充分性或準確性,也不承擔任何責任。

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Forward-looking statements in this press release relate to the use of proceeds of the Offering and the development of the Company's business. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.

本新聞稿可能包含基於當前預期的前瞻性陳述和信息。這些陳述不應被視爲對公司未來業績或業績的保證。本新聞稿中的前瞻性陳述涉及本次發行所得款項的使用和公司業務的發展。此類陳述涉及已知和未知的風險、不確定性和其他因素,可能導致實際結果、業績或成就與此類陳述所暗示的存在重大差異。

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company's future operations; competition; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals..

前瞻性信息受已知和未知的風險、不確定性和其他因素的影響,這些因素可能導致公司的實際業績、活動水平、業績或成就與此類前瞻性信息所表達或暗示的結果存在重大差異。此類風險和其他因素可能包括但不限於:一般業務、經濟、競爭、政治和社會的不確定性;一般資本市場狀況和證券市場價格;公司未來經營的實際業績;競爭;影響公司的立法變化;獲得和維持所需許可證和批准的能力、以可接受的條件獲得外部融資的時間和可用性;缺乏合格的熟練勞動力或關鍵人物的流失。

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

可能導致實際業績與前瞻性信息存在重大差異的其他風險因素的描述可在SEDAR+網站上公司的披露文件中找到,網址爲。儘管公司試圖確定可能導致實際業績與前瞻性信息中包含的結果存在重大差異的重要因素,但可能還有其他因素導致業績與預期、估計或預期的結果不符。因此,讀者不應過分依賴前瞻性信息。提醒讀者,上述因素清單並不詳盡。進一步提醒讀者不要過分依賴前瞻性信息,因爲無法保證前瞻性信息所依據的計劃、意圖或期望會實現。儘管管理層在編制時認爲此類信息是合理的,但可能被證明是不正確的,實際結果可能與預期結果存在重大差異。

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

公司的證券未根據經修訂的1933年《美國證券法》(“美國證券法”)或適用的州證券法進行註冊,未經註冊或未獲得此類註冊要求的適用豁免,不得向美國個人或 “美國個人”(該術語的定義見《美國證券法案》)或適用的州證券法進行發行或出售,或爲其賬戶或利益。本新聞稿不構成出售要約或徵求買入要約,也不得在美國或任何將此類要約、招攬或出售爲非法的司法管轄區出售證券。

Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

本警示聲明明確限制了本新聞稿中包含的前瞻性信息。本新聞稿中包含的前瞻性信息代表了公司截至本新聞稿發佈之日的預期,因此,在該日期之後可能會發生變化。但是,除非適用的證券法明確要求,否則公司明確否認任何更新或修改任何前瞻性信息的意圖或義務,無論是由於新信息、未來事件還是其他原因。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論